Analysis

GLP-1 DTC Telehealth — SWOT Analysis

A SWOT analysis of the direct-to-consumer telehealth model for GLP-1 drugs, built on 528 clones open to GLP-1: five strengths, weaknesses, opportunities and threats each, with the consumer evidence behind them.

Brox.AI· Published ·Also in 日本語
Who was asked
US consumer clones open to GLP-1, 528 clones
When
February 2026
How
Predicted responses from Brox clones, each built from a long-form interview with a real person, run on the Brox platform.
The full report GLP-1 DTC Telehealth — SWOT Analysis Open the report

Section 01: What the study found

  1. #

    80.4%

    trust a doctor's recommendation over any other channel

    base 528

  2. #

    312

    consideration drivers profiled

    base 528

Section 02: Where this sits

Ask this of your own customers: humans@brox.ai

More in Pharma & HCP

All in Pharma & HCP